Summary:

• Hyphens Pharma has signed an out-licensing, supply and commercialisation agreement granting Louis Widmer SA rights to market Cerapro MED Skin Barrier Cream in Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands​

• Cerapro MED is a patented, skin pH-lowering cream approved under the EU Medical Device Regulation (CE-marked) for treating atopic dermatitis by restoring skin barrier function and supporting the skin’s antimicrobial defences​

• Product launches are targeted for 2026 in the six European markets, with Hyphens Pharma to receive an upfront fee plus customary sales-based royalties under the agreement​

• Louis Widmer, a Swiss dermatology-focused cosmetics and pharmaceuticals company founded in 1960, will promote Cerapro primarily to dermatologists and paediatricians, positioning it as the new flagship of its Remederm line for dry and atopic skin​

• Hyphens frames the deal as a milestone for its proprietary dermatology portfolio and part of its broader strategy to expand internationally through science-backed products and partnerships, while it continues to build its ASEAN specialty pharma and digital health ecosystem​